Skip to content
  • Home
  • IOncology
  • Infectious Desease Frontier
  • IHepatology
  • Hematology Frontier
  • Conference topics
  • Experts Interviews
  • Informations
  • Live Broadcasting
  • Logout
MediaMedic

Connecting Medical Expertise through Media

  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations
  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations

#CML

Home » #CML
Imatinib compared with second-generation tyrosine kinase inhibitors in persons with chronic myeloid leukemia presenting in accelerated phase

Imatinib compared with second-generation tyrosine kinase inhibitors in persons with chronic myeloid leukemia presenting in accelerated phase

Posted by By Mourabit Halima 2024.03.07
In July 2023, a study led by Professor Qian Jiang from Peking University Institute of Hematology was published in the international academic journal ——American Journal of Hematology (IF=12.8). The title…
Read More
External Validation of Predictive Scoring Systems for Molecular Responses in Chronic Myeloid Leukemia Receiving Imatinib Therapy

External Validation of Predictive Scoring Systems for Molecular Responses in Chronic Myeloid Leukemia Receiving Imatinib Therapy

Posted by By Mourabit Halima 2024.03.07
In September 2023, a  study led by Professor Qian Jiang from Peking University Institute of Hematology was published in the international academic journal ——Leukemia(IF=11.4). The title of the study is…
Read More
Recent Posts
  • CSCO 2026 | Professor Yanxia Shi: Extending Endocrine-Based Treatment — CDK2/4/6 Inhibition Offers a Therapeutic Option for Mutation-Negative Patients After CDK4/6 Inhibitor Therapy
  • CSCO 2026 | Professor Biyun Wang: From Stratification to Precision — Treatment Strategies After CDK4/6 Inhibitor Resistance and the Clinical Positioning of the CDK2/4/6 Inhibitor Kermoxili
  • CSCO International Perspectives | Professor Kun Wang in Conversation With Professor Pier Paolo Berton Giachetti: From Experience to Evidence — The Path Toward Precision Treatment in Early HER2-Positive Breast Cancer
  • ESMO Preview | Professor Yongmei Yin: A New Breakthrough in HR+/HER2− Advanced Breast Cancer — Iza-bren Ushers in a New Era of Bispecific ADC Therapy
  • Personalized mRNA Vaccine Plus Pembrolizumab Reduces Recurrence and Metastasis in Melanoma
Recent Comments
    Archives
    • October 2026
    • September 2026
    • August 2026
    • July 2026
    • June 2026
    • May 2026
    • April 2026
    • March 2026
    • February 2026
    • January 2026
    • December 2025
    • November 2025
    • October 2025
    • September 2025
    • August 2025
    • July 2025
    • June 2025
    • May 2025
    • April 2025
    • March 2025
    • February 2025
    • January 2025
    • December 2024
    • November 2024
    • October 2024
    • September 2024
    • August 2024
    • July 2024
    • June 2024
    • May 2024
    • April 2024
    • March 2024
    • February 2024
    • January 2024
    • December 2023
    • November 2023
    • October 2023
    • August 2023
    Categories
    • Artificial intelligence
    • Hematology Frontier
    • Infectious Disease Frontier
    • International Hepatology
    • IOncology
    • Live broadcasting
    • Uncategorized
    • UroStream
    • LinkedIn
    • Twitter
    • Mail
    Related Media:
    Copyright 2026 — MediaMedic. All rights reserved. Blogun WordPress Theme
    Paris, France
    Scroll to Top